文献速递关节外科

芬兰登记系统中交叉韧带保留型全膝关节置换术的长期生存率如何

What Is the Long-term Survivorship of Cruciate-retaining TKA in the Finnish Registry?
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

基于芬兰关节置换登记系统2005至2015年四款最常用交叉韧带保留型全膝关节置换术(CR TKA)假体的数据,以任何原因翻修为终点,10年Kaplan-Meier生存率为94%至96%;校正年龄、性别、医院手术量和原发诊断后,Triathlon CR和Vanguard CR较Nexgen CR Flex翻修风险升高(HR均为1.4)。以髌骨二期表面置换为翻修终点时,Triathlon CR较Nexgen CR Flex风险升高(HR 1.8)。

要点

  • 四款CR TKA假体10年生存率分别为Nexgen CR Flex 96%、PFC Sigma CR 96%、Triathlon CR 94%、Vanguard CR 94%。
  • 校正混杂因素后,Triathlon CR和Vanguard CR较Nexgen CR Flex翻修风险升高,HR均为1.4(95%CI 1.2-1.6,p<0.01)。
  • 以髌骨二期表面置换为终点,Triathlon CR较Nexgen CR Flex翻修风险升高,HR 1.8(95%CI 1.4-2.2,p<0.01)。

核心结论

  • 尽管所研究假体间存在轻微差异,当前所研究假体的总体10年生存率良好。
  • 但研究假体间假体生存率存在差异,尤其在分析因晚期髌骨表面置换而翻修时。
  • 需要进一步研究校正更多医院和外科医生变量以检验和确认本研究结果。

研究设计与样本

  • 数据来自芬兰关节置换登记系统,该国超过95%的原发TKA被登记收录。
  • 评估2005至2015年间最常用的四款CR TKA设计:Triathlon CR(n=34,337)、Nexgen CR Flex(n=15,723)、PFC Sigma CR(n=15,541)和Vanguard CR(n=9461)。
  • 以任何原因翻修为终点,翻修定义为至少更换一个组件的再手术(包括衬垫更换)。
  • 对初次手术未行髌骨表面置换而翻修时行髌骨表面置换的病例作为单独终点进行分析。
  • 采用Cox多重回归模型校正医院手术量、年龄、性别和原发诊断后比较翻修风险。

主要发现

  • 平均随访时间:Triathlon CR 4.0年(范围0-11.0),Nexgen CR Flex 3.8年(范围0-11.0),PFC Sigma CR 5.1年(范围0-11.0),Vanguard CR 4.9年(范围0-10.9)(p<0.001)。
  • 10年Kaplan-Meier总体生存率:Nexgen CR Flex 96%(95%CI 95-96),PFC Sigma CR 96%(95%CI 96-97),Triathlon CR 94%(95%CI 93-95),Vanguard CR 94%(95%CI 93-95)。
  • 校正年龄、性别、医院手术量和原发诊断后,Triathlon CR(HR 1.4;95%CI 1.2-1.6;p<0.01)和Vanguard CR(HR 1.4;95%CI 1.2-1.6;p<0.01)较Nexgen CR Flex(参照假体)翻修风险升高。
  • 以髌骨表面置换翻修为终点,校正相同混杂变量后,Triathlon CR较Nexgen CR Flex翻修风险升高(HR 1.8;95%CI 1.4-2.2;p<0.01)。
  • 初次关节置换时髌骨表面置换率存在差异:Nexgen CR Flex 18.7%,PFC Sigma CR 18.4%,Triathlon CR 11.3%,Vanguard CR 14.4%,该差异在Cox模型中加以控制。

关键数值与推荐

  • 10年总体生存率:Nexgen CR Flex 96%(95%CI 95-96),PFC Sigma CR 96%(95%CI 96-97),Triathlon CR 94%(95%CI 93-95),Vanguard CR 94%(95%CI 93-95)。
  • 任何原因翻修风险:Triathlon CR较Nexgen CR Flex HR 1.4(95%CI 1.2-1.6;p<0.01);Vanguard CR较Nexgen CR Flex HR 1.4(95%CI 1.2-1.6;p<0.01)。
  • 髌骨表面置换翻修风险:Triathlon CR较Nexgen CR Flex HR 1.8(95%CI 1.4-2.2;p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究校正更多医院和外科医生变量以检验和确认本研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival of cruciate-retaining (CR) TKA is generally good, but there may be important differences in survivorship among devices, and different designs may not all be equally patellar-friendly. Large registry databases are needed to identify small but important differences between devices. QUESTIONS/PURPOSES: The purposes of this study were (1) to assess the long-term survivorship of the most common CR TKA devices with revision for any reason as the endpoint and compare the revision risk of these devices after controlling for the potentially confounding variables of age, sex, hospital volume, and primary diagnosis; and (2) to analyze these same devices with revision for secondary resurfacing of the patella as a separate endpoint. METHODS: Data were collected from the Finnish Arthroplasty Register. Over 95% of all primary TKAs are captured in the Finnish Register. We assessed Kaplan-Meier (KM) survivorship for each of the four most frequently used CR TKA designs used between years 2005 and 2015: Triathlon CR (n = 34,337), Nexgen CR Flex (n = 15,723), PFC Sigma CR (n = 15,541), and Vanguard CR (n = 9461), with revision for any reason as the endpoint. Revision was defined as a reoperation in which at least one of the components was exchanged (including insert exchange). Revisions in which the patella was not resurfaced at the primary operation and was resurfaced in the revision were studied as a separate endpoint. The mean followup times were 4.0 (range, 0-11.0) years for Triathlon CR, 3.8 (range, 0-11.0) years for Nexgen CR Flex, 5.1 (range, 0-11.0 ) years for PFC Sigma CR, and 4.9 (range, 0-10.9) years for Vanguard CR (p < 0.001). The group demographics were clinically comparable. We compared the risk of revision of these devices in the Cox multiple regression model with adjustment for hospital volume, age, sex, and primary diagnosis. There were some differences in the incidence of patellar resurfacing at the time of index arthroplasty (Nexgen CR flex 18.7%, PFC Sigma CR 18.4%, Triathlon CR 11.3%, Vanguard CR 14.4%), which was controlled by the Cox model. Implant survival analyses for Triathlon CR, Nexgen CR Flex, and PFC Sigma CR were also performed at the hospital level for the 25 largest TKA providers in Finland. RESULTS: The overall 10-year KM survivorships were 96% (95% confidence interval [CI], 95-96) for Nexgen CR Flex, 96% (95% CI, 96-97) for PFC Sigma CR, 94% (95% CI, 93-95) for Triathlon CR, and 94% (95% CI, 93-95) for Vanguard CR. After controlling for potential confounding variables like age, sex, hospital volume, and primary diagnosis, both Triathlon CR (hazard ratio [HR], 1.4; 95% CI, 1.2-1.6; p < 0.01) and Vanguard CR (HR, 1.4; 95% CI, 1.2-1.6; p < 0.01) had an increased risk for revision compared with the Nexgen CR Flex (the reference device). When revision with patellar resurfacing served as the endpoint, after controlling for those same confounding variables, Triathlon CR had a higher risk for revision than Nexgen CR Flex (HR, 1.8; 95% CI, 1.4-2.2; p < 0.01). CONCLUSIONS: Despite slight differences among the studied devices, the overall 10-year survivorship of the current devices studied was good. However, there were differences in implant survival between the study devices, especially when revision for late patellar resurfacing was analyzed. Further studies adjusted for additional hospital and surgeon variables will be needed to examine and confirm our results. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Montonen E, Laaksonen I, Matilainen M, et al. What Is the Long-term Survivorship of Cruciate-retaining TKA in the Finnish Registry? Clin Orthop Relat Res. 2018. PMID: 29406454. doi:10.1007/s11999.0000000000000202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。